Abivax with new CMO
Biguenet brings more than 25 years of experience in academic research and the biopharmaceutical industry. She succeeds Jean-Marc Steens, who will retire after six years as Abivax' CMO. Biguenet joins from Swiss biotech company Versantis, where she was also CMO and responsible for the pipeline from pre-clinical to phase 2b. She is a board-certified general and pediatric surgeon who completed her residency in France. She began her biopharmaceutical career at Roche, followed by various leadership positions at Biogen Idec (France), Bristol-Myers Squibb, Abbvie (USA) and Medicines for Malaria Venture (Switzerland).